patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_627716 | REC_0001801 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 19 | 18.7 | 68 | female | 0 | 19 | 3.7 | 0 | alectinib 600 mg BID | 35.6 | true | MSS | 2026-03-15T05:35:57.288847+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_519184 | REC_0001802 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 5.5 | 79 | female | 2 | 17 | 5.6 | 7 | alectinib 600 mg BID | 9.3 | false | MSS | 2026-03-15T05:35:57.289076+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_648227 | REC_0001803 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 28 | 18.8 | 70 | female | 1 | 16 | 4.1 | 5 | osimertinib 80 mg daily | 10.3 | true | MSI-H | 2026-03-15T05:35:57.289308+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_940510 | REC_0001804 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 18 | 20 | 61 | male | 1 | 17 | 6 | 6 | osimertinib 80 mg daily | 11 | true | MSI-H | 2026-03-15T05:35:57.289544+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_257637 | REC_0001805 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 22 | 13.7 | 71 | female | 2 | 5 | 4.6 | 1 | alectinib 600 mg BID | 14.7 | false | MSI-H | 2026-03-15T05:35:57.289776+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_844618 | REC_0001806 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 28 | 14 | 81 | female | 1 | 16 | 4.5 | 0 | alectinib 600 mg BID | 46.3 | true | MSS | 2026-03-15T05:35:57.290018+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_379429 | REC_0001807 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 3.5 | 85 | female | 2 | 85 | 5.4 | 6 | carboplatin + paclitaxel + pembrolizumab | 15.5 | true | MSS | 2026-03-15T05:35:57.290254+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_210992 | REC_0001808 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 19 | 12.9 | 55 | male | 1 | 10 | 5.2 | 7 | osimertinib 80 mg daily | 13.2 | true | MSS | 2026-03-15T05:35:57.290575+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_525029 | REC_0001809 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 30 | 5.5 | 81 | female | 1 | 24 | 2.9 | 6 | carboplatin + paclitaxel + pembrolizumab | 6.9 | true | MSS | 2026-03-15T05:35:57.290810+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_961621 | REC_0001810 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 26 | 2.6 | 78 | male | 1 | 4 | 6.2 | 1 | pembrolizumab 200 mg q3w | 10.8 | true | MSS | 2026-03-15T05:35:57.291041+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_683434 | REC_0001811 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 21 | 5.2 | 65 | male | 1 | 33 | 6.4 | 8 | carboplatin + paclitaxel + pembrolizumab | 9.3 | true | MSS | 2026-03-15T05:35:57.291278+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_728477 | REC_0001812 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 27 | 16.8 | 66 | female | 1 | 12 | 5.3 | 5 | sotorasib 960 mg daily | 7.3 | false | MSI-H | 2026-03-15T05:35:57.291513+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_944386 | REC_0001813 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 30 | 7.2 | 58 | male | 1 | 26 | 7 | 1 | entrectinib 600 mg daily | 25.4 | false | MSS | 2026-03-15T05:35:57.291747+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_588123 | REC_0001814 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 12.4 | 60 | female | 1 | 8 | 5.7 | 6 | sotorasib 960 mg daily | 11.2 | false | MSI-H | 2026-03-15T05:35:57.291982+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_771195 | REC_0001815 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 5.1 | 71 | female | 2 | 70 | 5.9 | 7 | carboplatin + paclitaxel + pembrolizumab | 5.4 | false | MSS | 2026-03-15T05:35:57.292281+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_824773 | REC_0001816 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 20 | 10.3 | 83 | female | 1 | 11 | 6 | 8 | sotorasib 960 mg daily | 12 | false | MSI-H | 2026-03-15T05:35:57.292534+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_695152 | REC_0001817 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 34 | 17.5 | 81 | female | 2 | 20 | 6.1 | 8 | osimertinib 80 mg daily | 16.6 | false | MSS | 2026-03-15T05:35:57.292770+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_489090 | REC_0001818 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 14 | 9 | 57 | male | 1 | 15 | 7.8 | 1 | sotorasib 960 mg daily | 4.1 | true | MSS | 2026-03-15T05:35:57.293003+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_847062 | REC_0001819 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 23 | 5.4 | 71 | female | 2 | 72 | 6 | 7 | pembrolizumab 200 mg q3w | 11.8 | true | MSS | 2026-03-15T05:35:57.293238+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_279836 | REC_0001820 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 29 | 5.9 | 80 | female | 1 | 12 | 4.5 | 6 | sotorasib 960 mg daily | 12.6 | false | MSS | 2026-03-15T05:35:57.293470+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_459118 | REC_0001821 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 18 | 11.9 | 64 | female | 0 | 15 | 4.3 | 1 | osimertinib 80 mg daily | 12.7 | false | MSS | 2026-03-15T05:35:57.293775+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_540217 | REC_0001822 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 19 | 12.4 | 75 | female | 0 | 21 | 5.7 | 6 | osimertinib 80 mg daily | 11.2 | true | MSS | 2026-03-15T05:35:57.294011+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_743881 | REC_0001823 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 26 | 10.3 | 61 | male | 1 | 21 | 6.3 | 2 | pembrolizumab 200 mg q3w | 10.1 | false | MSI-H | 2026-03-15T05:35:57.294247+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_570707 | REC_0001824 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 19 | 15.6 | 65 | male | 1 | 25 | 3.2 | 6 | sotorasib 960 mg daily | 11.8 | false | MSI-H | 2026-03-15T05:35:57.294482+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_807828 | REC_0001825 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 21 | 9.4 | 62 | male | 1 | 34 | 4.3 | 3 | carboplatin + paclitaxel + pembrolizumab | 12.6 | false | MSS | 2026-03-15T05:35:57.294715+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_697184 | REC_0001826 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 21 | 14.5 | 59 | female | 1 | 11 | 6.2 | 2 | osimertinib 80 mg daily | 20.3 | false | MSS | 2026-03-15T05:35:57.294950+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_599362 | REC_0001827 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 21 | 5.3 | 66 | male | 0 | 68 | 3.9 | 6 | carboplatin + paclitaxel + pembrolizumab | 5.2 | false | MSS | 2026-03-15T05:35:57.295180+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_506605 | REC_0001828 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 10.9 | 58 | male | 0 | 16 | 4.8 | 5 | entrectinib 600 mg daily | 4 | false | MSI-H | 2026-03-15T05:35:57.295416+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_260532 | REC_0001829 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 30 | 12.7 | 73 | female | 2 | 24 | 5 | 6 | osimertinib 80 mg daily | 6.5 | false | MSI-H | 2026-03-15T05:35:57.295646+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_731870 | REC_0001830 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 21 | 10.4 | 52 | female | 0 | 13 | 5.4 | 4 | entrectinib 600 mg daily | 8.8 | false | MSI-H | 2026-03-15T05:35:57.295881+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_846617 | REC_0001831 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 20 | 12.7 | 75 | male | 3 | 17 | 6.3 | 2 | sotorasib 960 mg daily | 19.7 | false | MSI-H | 2026-03-15T05:35:57.296192+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_143364 | REC_0001832 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 19 | 5 | 57 | female | 1 | 15 | 7.4 | 2 | pembrolizumab 200 mg q3w | 20.9 | false | MSS | 2026-03-15T05:35:57.296439+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_915093 | REC_0001833 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 31 | 15.5 | 56 | female | 0 | 16 | 6 | 2 | entrectinib 600 mg daily | 4.9 | true | MSS | 2026-03-15T05:35:57.296680+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_431423 | REC_0001834 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 24 | 6.2 | 73 | female | 2 | 50 | 4.3 | 6 | pembrolizumab 200 mg q3w | 7.5 | false | MSS | 2026-03-15T05:35:57.296981+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_546852 | REC_0001835 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 26 | 4.1 | 48 | male | 0 | 71 | 3.4 | 1 | carboplatin + paclitaxel + pembrolizumab | 15.7 | false | MSS | 2026-03-15T05:35:57.297223+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_875623 | REC_0001836 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 23 | 13 | 70 | female | 2 | 11 | 6.4 | 1 | osimertinib 80 mg daily | 24 | true | MSI-H | 2026-03-15T05:35:57.297460+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_354645 | REC_0001837 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 25 | 6.9 | 75 | female | 1 | 11 | 4.8 | 9 | pembrolizumab 200 mg q3w | 11.4 | true | MSS | 2026-03-15T05:35:57.297688+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_481619 | REC_0001838 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 7.5 | 66 | female | 0 | 18 | 6.7 | 7 | sotorasib 960 mg daily | 10.9 | false | MSS | 2026-03-15T05:35:57.297915+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_676289 | REC_0001839 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 11.2 | 64 | male | 1 | 14 | 6.1 | 5 | sotorasib 960 mg daily | 17 | true | MSI-H | 2026-03-15T05:35:57.298153+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_871479 | REC_0001840 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 31 | 11 | 73 | female | 2 | 15 | 5.9 | 2 | pembrolizumab 200 mg q3w | 13.1 | true | MSI-H | 2026-03-15T05:35:57.298383+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_359761 | REC_0001841 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 10.6 | 55 | male | 1 | 25 | 4.5 | 6 | alectinib 600 mg BID | 6.3 | true | MSS | 2026-03-15T05:35:57.298618+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_244562 | REC_0001842 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 22 | 7.2 | 55 | male | 1 | 9 | 3.7 | 6 | pembrolizumab 200 mg q3w | 13.5 | true | MSS | 2026-03-15T05:35:57.298861+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_283635 | REC_0001843 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 24 | 8.9 | 63 | male | 1 | 10 | 6.8 | 1 | sotorasib 960 mg daily | 19.3 | false | MSS | 2026-03-15T05:35:57.299110+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_955285 | REC_0001844 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 24 | 14 | 61 | female | 1 | 20 | 6.6 | 2 | sotorasib 960 mg daily | 7.3 | false | MSI-H | 2026-03-15T05:35:57.299360+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_822332 | REC_0001845 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 16 | 13.2 | 71 | female | 2 | 19 | 6.7 | 9 | osimertinib 80 mg daily | 13.2 | true | MSI-H | 2026-03-15T05:35:57.299607+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_914696 | REC_0001846 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 33 | 7.2 | 69 | female | 1 | 55 | 4.7 | 5 | pembrolizumab 200 mg q3w | 4 | false | MSS | 2026-03-15T05:35:57.299842+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_985236 | REC_0001847 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 30 | 8.4 | 78 | male | 3 | 17 | 7.5 | 2 | alectinib 600 mg BID | 26.1 | false | MSS | 2026-03-15T05:35:57.300222+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_191185 | REC_0001848 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 23 | 11.1 | 60 | male | 0 | 19 | 6.7 | 1 | alectinib 600 mg BID | 16 | true | MSI-H | 2026-03-15T05:35:57.300477+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_109696 | REC_0001849 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 19 | 14 | 77 | female | 1 | 11 | 5.3 | 2 | osimertinib 80 mg daily | 29.3 | true | MSI-H | 2026-03-15T05:35:57.300712+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_530978 | REC_0001850 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 21 | 8.4 | 72 | female | 1 | 39 | 5.5 | 7 | carboplatin + paclitaxel + pembrolizumab | 13.1 | false | MSS | 2026-03-15T05:35:57.300942+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_750495 | REC_0001851 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 18 | 13.1 | 73 | female | 1 | 25 | 5.3 | 1 | pembrolizumab 200 mg q3w | 28.4 | false | MSI-H | 2026-03-15T05:35:57.301181+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_917923 | REC_0001852 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 26 | 11 | 65 | male | 0 | 7 | 7.5 | 2 | sotorasib 960 mg daily | 25.2 | true | MSI-H | 2026-03-15T05:35:57.301416+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_956976 | REC_0001853 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 11.2 | 62 | female | 0 | 22 | 5.9 | 5 | osimertinib 80 mg daily | 12.8 | true | MSS | 2026-03-15T05:35:57.301655+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_558842 | REC_0001854 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 12.4 | 72 | male | 1 | 14 | 5.5 | 3 | osimertinib 80 mg daily | 12.2 | false | MSS | 2026-03-15T05:35:57.301890+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_988899 | REC_0001855 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 28 | 4 | 63 | female | 0 | 14 | 6.6 | 6 | pembrolizumab 200 mg q3w | 7.8 | true | MSS | 2026-03-15T05:35:57.302126+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_547534 | REC_0001856 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 27 | 13.7 | 57 | female | 0 | 12 | 4.6 | 6 | osimertinib 80 mg daily | 7.9 | true | MSI-H | 2026-03-15T05:35:57.302362+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_948248 | REC_0001857 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 21 | 6.3 | 72 | female | 2 | 44 | 5.1 | 1 | carboplatin + paclitaxel + pembrolizumab | 20.6 | false | MSS | 2026-03-15T05:35:57.302593+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_650152 | REC_0001858 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 32 | 5.1 | 59 | male | 0 | 51 | 4.8 | 6 | pembrolizumab 200 mg q3w | 4 | true | MSS | 2026-03-15T05:35:57.302826+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_489115 | REC_0001859 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 13 | 68 | female | 0 | 14 | 4.7 | 5 | osimertinib 80 mg daily | 11.3 | true | MSS | 2026-03-15T05:35:57.303056+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_847978 | REC_0001860 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 18.7 | 62 | female | 0 | 12 | 5.4 | 8 | osimertinib 80 mg daily | 8.5 | false | MSS | 2026-03-15T05:35:57.303344+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_170216 | REC_0001861 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 23 | 14.6 | 68 | female | 1 | 15 | 4.5 | 0 | osimertinib 80 mg daily | 37.1 | true | MSI-H | 2026-03-15T05:35:57.303584+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_108903 | REC_0001862 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 18 | 6.5 | 61 | female | 1 | 12 | 5.8 | 2 | carboplatin + paclitaxel + pembrolizumab | 19 | true | MSS | 2026-03-15T05:35:57.303823+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_451753 | REC_0001863 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 31 | 4.8 | 78 | female | 1 | 32 | 6.4 | 4 | carboplatin + paclitaxel + pembrolizumab | 17 | true | MSS | 2026-03-15T05:35:57.304164+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_696315 | REC_0001864 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 7.9 | 54 | female | 0 | 37 | 6 | 5 | carboplatin + paclitaxel + pembrolizumab | 15.1 | false | MSS | 2026-03-15T05:35:57.304463+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_676909 | REC_0001865 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 24 | 9.4 | 77 | female | 1 | 24 | 4.5 | 1 | osimertinib 80 mg daily | 12.8 | false | MSS | 2026-03-15T05:35:57.304731+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_900896 | REC_0001866 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 26 | 9.6 | 59 | female | 1 | 20 | 5.4 | 1 | entrectinib 600 mg daily | 21.8 | true | MSS | 2026-03-15T05:35:57.305010+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_354262 | REC_0001867 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 28 | 11.8 | 54 | female | 0 | 14 | 5 | 8 | sotorasib 960 mg daily | 9.1 | false | MSI-H | 2026-03-15T05:35:57.305299+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_281965 | REC_0001868 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 27 | 13.5 | 69 | female | 0 | 10 | 4.9 | 5 | osimertinib 80 mg daily | 7.9 | true | MSI-H | 2026-03-15T05:35:57.305558+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_827947 | REC_0001869 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 21 | 6.5 | 66 | female | 0 | 25 | 4.9 | 6 | pembrolizumab 200 mg q3w | 6.4 | false | MSS | 2026-03-15T05:35:57.305798+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_591458 | REC_0001870 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 20 | 5.6 | 57 | female | 1 | 33 | 5.4 | 6 | pembrolizumab 200 mg q3w | 12.3 | true | MSS | 2026-03-15T05:35:57.306037+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_995138 | REC_0001871 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 12.5 | 62 | male | 1 | 19 | 5.4 | 6 | sotorasib 960 mg daily | 14.9 | false | MSI-H | 2026-03-15T05:35:57.306279+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_308696 | REC_0001872 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 27 | 12.2 | 76 | female | 2 | 8 | 5 | 8 | alectinib 600 mg BID | 14 | true | MSI-H | 2026-03-15T05:35:57.306518+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_239786 | REC_0001873 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 25 | 10.2 | 73 | female | 1 | 23 | 5.3 | 2 | osimertinib 80 mg daily | 13.7 | false | MSI-H | 2026-03-15T05:35:57.306882+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_986308 | REC_0001874 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 27 | 9.5 | 61 | female | 1 | 18 | 6.6 | 0 | alectinib 600 mg BID | 20.6 | false | MSS | 2026-03-15T05:35:57.307123+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_550477 | REC_0001875 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 19 | 8.4 | 67 | female | 0 | 51 | 4.6 | 6 | carboplatin + paclitaxel + pembrolizumab | 15.2 | false | MSS | 2026-03-15T05:35:57.307356+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_941082 | REC_0001876 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 6.3 | 70 | female | 1 | 70 | 6.4 | 4 | carboplatin + paclitaxel + pembrolizumab | 9.3 | false | MSS | 2026-03-15T05:35:57.307585+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_842511 | REC_0001877 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 27 | 8.7 | 73 | female | 1 | 17 | 5 | 3 | pembrolizumab 200 mg q3w | 14.8 | false | MSS | 2026-03-15T05:35:57.307818+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_305868 | REC_0001878 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 16.7 | 66 | female | 0 | 10 | 4.6 | 5 | osimertinib 80 mg daily | 14.1 | false | MSI-H | 2026-03-15T05:35:57.308049+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_954558 | REC_0001879 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 21 | 13.2 | 60 | male | 0 | 18 | 5.3 | 2 | osimertinib 80 mg daily | 22.6 | false | MSI-H | 2026-03-15T05:35:57.308354+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_940550 | REC_0001880 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 22 | 11.3 | 72 | male | 3 | 12 | 6.7 | 2 | osimertinib 80 mg daily | 18.6 | true | MSS | 2026-03-15T05:35:57.308593+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_257748 | REC_0001881 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 19 | 10.1 | 70 | female | 1 | 11 | 5.6 | 3 | entrectinib 600 mg daily | 7 | true | MSI-H | 2026-03-15T05:35:57.308829+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_225886 | REC_0001882 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 27 | 18.8 | 66 | female | 0 | 17 | 4.8 | 0 | sotorasib 960 mg daily | 44.4 | false | MSS | 2026-03-15T05:35:57.309064+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_720640 | REC_0001883 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 16.9 | 58 | male | 0 | 15 | 6.3 | 7 | osimertinib 80 mg daily | 9 | false | MSI-H | 2026-03-15T05:35:57.309297+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_298494 | REC_0001884 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 32 | 6.7 | 76 | male | 2 | 37 | 6.5 | 7 | carboplatin + paclitaxel + pembrolizumab | 15.8 | false | MSS | 2026-03-15T05:35:57.309527+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_711846 | REC_0001885 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 25 | 10.7 | 56 | female | 0 | 5 | 4.5 | 2 | osimertinib 80 mg daily | 4.2 | false | MSS | 2026-03-15T05:35:57.309761+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_302185 | REC_0001886 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 12.5 | 75 | female | 2 | 14 | 4.9 | 6 | sotorasib 960 mg daily | 14.7 | false | MSI-H | 2026-03-15T05:35:57.310066+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_639316 | REC_0001887 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 20 | 7.3 | 69 | female | 0 | 21 | 5.1 | 7 | alectinib 600 mg BID | 13 | false | MSS | 2026-03-15T05:35:57.310304+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_319004 | REC_0001888 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 8.6 | 61 | male | 0 | 20 | 6.2 | 5 | entrectinib 600 mg daily | 19.4 | true | MSS | 2026-03-15T05:35:57.310536+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_411834 | REC_0001889 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 24 | 7.5 | 62 | male | 0 | 8 | 3.7 | 1 | pembrolizumab 200 mg q3w | 15.5 | true | MSS | 2026-03-15T05:35:57.310767+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_482488 | REC_0001890 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 21 | 18.5 | 73 | female | 1 | 14 | 7.5 | 2 | osimertinib 80 mg daily | 17.2 | false | MSI-H | 2026-03-15T05:35:57.311005+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_360991 | REC_0001891 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 26 | 4.5 | 78 | female | 2 | 16 | 5.1 | 1 | alectinib 600 mg BID | 25.6 | false | MSS | 2026-03-15T05:35:57.311234+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_278974 | REC_0001892 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 22 | 10.1 | 69 | female | 1 | 16 | 7.2 | 1 | osimertinib 80 mg daily | 8.9 | false | MSS | 2026-03-15T05:35:57.311462+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_394087 | REC_0001893 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 7.2 | 66 | female | 1 | 19 | 6.5 | 7 | alectinib 600 mg BID | 5.1 | true | MSS | 2026-03-15T05:35:57.311691+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_346752 | REC_0001894 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 25 | 4.5 | 73 | female | 1 | 70 | 7.8 | 1 | carboplatin + paclitaxel + pembrolizumab | 10.2 | true | MSS | 2026-03-15T05:35:57.311919+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_490777 | REC_0001895 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 17.1 | 72 | female | 2 | 9 | 6.9 | 6 | osimertinib 80 mg daily | 10.6 | true | MSI-H | 2026-03-15T05:35:57.312187+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_748712 | REC_0001896 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 30 | 16.3 | 59 | male | 1 | 11 | 5.5 | 1 | entrectinib 600 mg daily | 16.1 | true | MSS | 2026-03-15T05:35:57.312427+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_414744 | REC_0001897 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 20 | 1.6 | 57 | female | 0 | 29 | 7.3 | 1 | carboplatin + paclitaxel + pembrolizumab | 20.9 | false | MSS | 2026-03-15T05:35:57.312662+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_935101 | REC_0001898 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 20 | 14.3 | 75 | female | 2 | 26 | 7.8 | 2 | entrectinib 600 mg daily | 21.4 | true | MSS | 2026-03-15T05:35:57.312899+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_457689 | REC_0001899 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 23 | 10.4 | 56 | male | 0 | 15 | 4.2 | 2 | sotorasib 960 mg daily | 34.8 | false | MSI-H | 2026-03-15T05:35:57.313186+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_141592 | REC_0001900 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 30 | 14.5 | 69 | female | 1 | 15 | 5.5 | 2 | sotorasib 960 mg daily | 18.5 | true | MSS | 2026-03-15T05:35:57.313423+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.